Recent developments highlight Dermata's strategic shift to OTC skincare products, clinical trial progress, financial results, and capital raising activities.

• Dermata announced a private placement valued at up to $12.4 million in December 2025 [N1].
• The company plans to launch its first OTC acne kit in mid-2026 [N2].
• Dermata reported a narrower loss in Q2 2025 [N3].
• Enrollment in the DMT310 Phase 3 STAR-1 trial was completed by December 2024 [N4].
• Dermata received FDA approval to begin pivotal study of its acne drug in late 2023 [N6].
• Positive FDA responses for the acne candidate were reported in April 2023 [N8].

Dermata's successful transition from prescription drug development to OTC and cosmetic skincare products leverages its unique Bioneedle technology and clinical expertise. Positive Phase 3 trial results for its lead acne drug demonstrate scientific validation. The planned mid-2026 launch of its first cosmetic and OTC acne products, combined with a dual-channel marketing strategy targeting both consumers and skincare professionals, could enable rapid market penetration. The exclusive supply agreement for Spongilla raw material and ongoing efforts to expand the product portfolio to address multiple skin conditions may create diversified revenue streams. The recent private placement provides additional capital to support commercialization efforts. If Dermata effectively executes its strategy, it may capture significant market share in the growing skincare industry.

Dermata faces substantial risks including regulatory challenges in transitioning from prescription to OTC monograph pathways, which could delay or prevent product launches and require costly reformulations. The ongoing license dispute with Villani, Inc. could result in loss of rights to key technology or products. The company has a history of net losses, limited operating history as a commercial entity, and uncertainty about achieving or sustaining profitability. Competition from large, well-funded consumer products companies is intense. Supply chain disruptions, counterfeit products, and operational execution risks could adversely affect product availability and brand reputation. The company’s liquidity, while currently adequate, may require additional capital raises, which could dilute shareholders or constrain operations.

Dermata Therapeutics' moat is centered on its proprietary Bioneedle technology derived from Spongilla lacustris, a unique freshwater sponge with distinctive organic and mechanical properties. The company holds an exclusive supply agreement with Reka-Farm LLC for this raw material, which supports product differentiation. Dermata's clinical knowledge from its Rx dermatology background and its planned certification program for skincare professionals aim to build brand credibility and professional endorsement. The combination of natural, science-backed ingredients and a dual-channel commercialization strategy (DTC and B2B) may provide competitive advantages. However, the company faces significant competition from large established consumer products companies and must navigate regulatory complexities in transitioning from Rx to OTC products. Intellectual property protection, supply exclusivity, and professional network development are key components of its competitive positioning.

• Regulatory Risks: Transitioning from prescription drug development to OTC monograph pathways introduces risks of delays, reformulations, additional testing, and FDA compliance challenges that could impact product launches and commercialization timelines [S2].
• License Dispute: Dermata is engaged in a dispute with licensor Villani, Inc. regarding the strategic shift to OTC products and license terms, which could lead to arbitration or termination of the license agreement, potentially affecting product rights [S1].
• Competitive Pressure: The skincare market is highly competitive with large established companies having greater financial resources, which may impact Dermata's ability to compete effectively on advertising, innovation, and pricing [S2].
• Financial and Operational Risks: Dermata has a history of net losses, limited commercial operating history, and uncertainty about achieving profitability. The company depends on third-party manufacturers, suppliers, and delivery providers, with risks of disruptions affecting product availability and sales [S1].
• Counterfeit Products: The presence of counterfeit or unauthorized versions of Dermata's products, especially in the OTC market, could harm consumers and damage the company's reputation and sales [S2].
• Liquidity and Capital Needs: While Dermata had $7.5 million in cash at year-end 2025, it may require additional capital to fund commercialization and operations, with risks related to capital availability and dilution [S1].

• Dermata Therapeutics, Inc. is a scientific leader in skincare focused on developing and commercializing products addressing common and underserved skin conditions [S1].
• Originally focused on prescription (Rx) products, Dermata's lead asset was XYNGARI (DMT310), studied in Phase 3 trials for moderate-to-severe acne, achieving statistically significant results in March 2025 [S1].
• In September 2025, Dermata shifted strategy from Rx to direct-to-consumer (DTC) and business-to-business (B2B) OTC skincare products to accelerate commercialization, reduce regulatory burden, and decrease development expenses [S1].
• The company plans to leverage its Spongilla lacustris-derived Bioneedle technology in cosmetic and OTC skincare products, including a foundational skin renewal treatment and an OTC acne clearing treatment [S1].
• The first cosmetic product launch is planned for mid-2026, followed shortly by the OTC acne product [S1].
• Dermata intends to commercialize products via a dual-channel strategy: DTC sales through its website and B2B sales to licensed aestheticians, dermatologists, and med spas, supported by a certification program for skincare professionals [S1].
• The company is exploring additional skincare products targeting conditions such as psoriasis and seborrheic dermatitis using its Bioneedle technology [S1].
• Dermata holds an exclusive supply agreement with Reka-Farm LLC for Spongilla raw materials, with quality controls and capacity to support commercial launch [S1].
• The company reported a net loss of approximately $7.6 million for the fiscal year ended December 31, 2025, with basic and diluted EPS of -$8.16 per share [S1].
• As of December 31, 2025, Dermata had cash and cash equivalents of approximately $7.5 million and a strong liquidity position with a current ratio of 7.66 and cash ratio of 4.96 [S1].
• Dermata completed enrollment in the DMT310 Phase 3 STAR-1 trial by December 2024 and announced positive Phase 3 results in March 2025 [N4][S1].
• The company announced a private placement valued at up to $12.4 million in December 2025 [N1].
• Dermata announced plans to launch its first OTC acne kit in mid-2026 [N2].
• The company reported a narrower loss in Q2 2025 [N3].
• Dermata received FDA nod to begin pivotal study of acne drug in late 2023 and positive FDA responses for its acne candidate in 2023 [N6][N8].
• Dermata is engaged in a dispute with its licensor Villani, Inc. regarding the strategic shift to OTC products and license agreement terms; the license remains in force while discussions continue [S1].
• The company faces regulatory risks related to the transition from Rx to OTC monograph pathways, including potential delays, reformulations, and FDA compliance challenges [S2].
• Dermata operates in a highly competitive skincare market with large established consumer products companies as competitors [S2].
• The company has not yet launched a commercial product and has a history of net losses [S1].
• Dermata's business depends on third-party manufacturers, suppliers, and delivery service providers, with risks of disruptions affecting product availability [S1].
• The company plans to build a network of certified skincare professionals to support in-office treatments and product adoption [S1].
• Dermata intends to strengthen its intellectual property portfolio and maintain exclusivity and supply agreements as competitive advantages [S1].
• The company is subject to risks including counterfeit products, regulatory changes, competition, and operational challenges [S2].
• Dermata's financial condition includes substantial accumulated deficit and uncertainty about achieving or sustaining profitability [S1].
• The company estimates its existing cash will fund operations into early 2027 but may require additional capital to support commercialization [S1].